rudipharm limited
rudipharm limited Company Information
Company Number
09987370
Next Accounts
Jun 2025
Directors
Shareholders
ruprai group limited
kalvinder ruprai
Group Structure
View All
Industry
Manufacture of basic pharmaceutical products
Registered Address
unit 6 i.o.centre, salbrook road ind estate, salfords, surrey, RH1 5GJ
Website
www.northstarhomehealth.comrudipharm limited Estimated Valuation
Pomanda estimates the enterprise value of RUDIPHARM LIMITED at £30.3m based on a Turnover of £15.2m and 1.99x industry multiple (adjusted for size and gross margin).
rudipharm limited Estimated Valuation
Pomanda estimates the enterprise value of RUDIPHARM LIMITED at £38.1m based on an EBITDA of £4.5m and a 8.53x industry multiple (adjusted for size and gross margin).
rudipharm limited Estimated Valuation
Pomanda estimates the enterprise value of RUDIPHARM LIMITED at £5.8m based on Net Assets of £3.3m and 1.75x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Rudipharm Limited Overview
Rudipharm Limited is a live company located in salfords, RH1 5GJ with a Companies House number of 09987370. It operates in the manufacture of basic pharmaceutical products sector, SIC Code 21100. Founded in February 2016, it's largest shareholder is ruprai group limited with a 75% stake. Rudipharm Limited is a young, mid sized company, Pomanda has estimated its turnover at £15.2m with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Rudipharm Limited Health Check
Pomanda's financial health check has awarded Rudipharm Limited a 4.5 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 4 areas for improvement. Company Health Check FAQs
3 Strong
5 Regular
4 Weak
Size
annual sales of £15.2m, make it smaller than the average company (£32.5m)
£15.2m - Rudipharm Limited
£32.5m - Industry AVG
Growth
3 year (CAGR) sales growth of 62%, show it is growing at a faster rate (4.9%)
- Rudipharm Limited
4.9% - Industry AVG
Production
with a gross margin of 38.9%, this company has a comparable cost of product (38.3%)
38.9% - Rudipharm Limited
38.3% - Industry AVG
Profitability
an operating margin of 29.4% make it more profitable than the average company (6.2%)
29.4% - Rudipharm Limited
6.2% - Industry AVG
Employees
with 4 employees, this is below the industry average (113)
4 - Rudipharm Limited
113 - Industry AVG
Pay Structure
on an average salary of £70.5k, the company has an equivalent pay structure (£62.5k)
£70.5k - Rudipharm Limited
£62.5k - Industry AVG
Efficiency
resulting in sales per employee of £3.8m, this is more efficient (£401.7k)
£3.8m - Rudipharm Limited
£401.7k - Industry AVG
Debtor Days
it gets paid by customers after 68 days, this is near the average (58 days)
68 days - Rudipharm Limited
58 days - Industry AVG
Creditor Days
its suppliers are paid after 32 days, this is quicker than average (37 days)
32 days - Rudipharm Limited
37 days - Industry AVG
Stock Days
it holds stock equivalent to 114 days, this is in line with average (95 days)
114 days - Rudipharm Limited
95 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 0 weeks, this is less cash available to meet short term requirements (9 weeks)
0 weeks - Rudipharm Limited
9 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 47.7%, this is a similar level of debt than the average (46.5%)
47.7% - Rudipharm Limited
46.5% - Industry AVG
RUDIPHARM LIMITED financials
Rudipharm Limited's latest turnover from September 2023 is £15.2 million and the company has net assets of £3.3 million. According to their latest financial statements, Rudipharm Limited has 4 employees and maintains cash reserves of £15.7 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Feb 2020 | Feb 2019 | Feb 2018 | Feb 2017 | |
|---|---|---|---|---|---|---|---|---|
| Turnover | 15,187,433 | 1,743,168 | ||||||
| Other Income Or Grants | 0 | 0 | ||||||
| Cost Of Sales | 9,278,690 | 1,419,350 | ||||||
| Gross Profit | 5,908,743 | 323,818 | 58,925 | |||||
| Admin Expenses | 1,439,531 | 1,128,860 | ||||||
| Operating Profit | 4,469,212 | -805,042 | ||||||
| Interest Payable | 595 | 564 | 177 | |||||
| Interest Receivable | 0 | 0 | 0 | |||||
| Pre-Tax Profit | 4,468,617 | -805,606 | -687,294 | |||||
| Tax | 0 | 0 | 82,031 | |||||
| Profit After Tax | 4,468,617 | -805,606 | -605,263 | |||||
| Dividends Paid | 0 | 0 | 0 | |||||
| Retained Profit | 4,468,617 | -805,606 | -605,263 | |||||
| Employee Costs | 281,944 | 260,247 | ||||||
| Number Of Employees | 4 | 4 | 3 | 3 | 3 | 2 | ||
| EBITDA* | 4,471,654 | -801,785 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Feb 2020 | Feb 2019 | Feb 2018 | Feb 2017 | |
|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 7,327 | 9,769 | 11,682 | 13,676 | 16,011 | 20,572 | 6,656 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 7,327 | 9,769 | 11,682 | 13,676 | 16,011 | 20,572 | 6,656 | 0 |
| Stock & work in progress | 2,909,760 | 205,658 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 2,842,637 | 402,763 | 226,535 | 768,008 | 542,009 | 297,944 | 191,363 | 100 |
| Group Debtors | 141,316 | 40,800 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 408,490 | 38,474 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 15,720 | 24,779 | 5,457 | 0 | 0 | 0 | 0 | 0 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 6,317,923 | 712,474 | 231,992 | 768,008 | 542,009 | 297,944 | 191,363 | 100 |
| total assets | 6,325,250 | 722,243 | 243,674 | 781,684 | 558,020 | 318,516 | 198,019 | 100 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 817,832 | 392,108 | 599,358 | 528,189 | 590,315 | 170,430 | 197,786 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 2,200,091 | 1,491,425 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current liabilities | 3,017,923 | 1,883,533 | 599,358 | 528,189 | 590,315 | 170,430 | 197,786 | 0 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 2,400 | 1,500 | 1,500 | 1,500 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 1,516 | 3,042 | 2,205 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 3,916 | 4,542 | 3,705 | 1,500 | 0 |
| total liabilities | 3,017,923 | 1,883,533 | 599,358 | 532,105 | 594,857 | 174,135 | 199,286 | 0 |
| net assets | 3,307,327 | -1,161,290 | -355,684 | 249,579 | -36,837 | 144,381 | -1,267 | 100 |
| total shareholders funds | 3,307,327 | -1,161,290 | -355,684 | 249,579 | -36,837 | 144,381 | -1,267 | 100 |
| Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Feb 2020 | Feb 2019 | Feb 2018 | Feb 2017 | |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Operating Profit | 4,469,212 | -805,042 | ||||||
| Depreciation | 2,442 | 3,257 | 1,994 | 0 | ||||
| Amortisation | 0 | 0 | 0 | 0 | ||||
| Tax | 0 | 0 | 82,031 | |||||
| Stock | 2,704,102 | 205,658 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 2,910,406 | 255,502 | -541,473 | 470,064 | 244,065 | 106,581 | 191,263 | 100 |
| Creditors | 425,724 | -207,250 | 71,169 | 357,759 | 419,885 | -27,356 | 197,786 | 0 |
| Accruals and Deferred Income | 708,666 | 1,491,425 | -2,400 | 900 | 0 | 0 | 1,500 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | -1,516 | -689 | 837 | 2,205 | 0 | 0 |
| Cash flow from operations | -8,464 | 21,230 | ||||||
| Investing Activities | ||||||||
| capital expenditure | 0 | 0 | ||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | 0 | 0 | ||||||
| Financing Activities | ||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||
| interest | -595 | -564 | -177 | |||||
| cash flow from financing | -595 | -564 | -177 | |||||
| cash and cash equivalents | ||||||||
| cash | -9,059 | 19,322 | 5,457 | 0 | 0 | 0 | 0 | 0 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | -9,059 | 19,322 | 5,457 | 0 | 0 | 0 | 0 | 0 |
rudipharm limited Credit Report and Business Information
Rudipharm Limited Competitor Analysis
Perform a competitor analysis for rudipharm limited by selecting its closest rivals, whether from the MANUFACTURING sector, other mid companies, companies in RH1 area or any other competitors across 12 key performance metrics.
rudipharm limited Ownership
RUDIPHARM LIMITED group structure
Rudipharm Limited has 1 subsidiary company.
Ultimate parent company
1 parent
RUDIPHARM LIMITED
09987370
1 subsidiary
rudipharm limited directors
Rudipharm Limited currently has 1 director, Mr Kalvinder Ruprai serving since Feb 2016.
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Kalvinder Ruprai | England | 55 years | Feb 2016 | - | Director |
P&L
September 2023turnover
15.2m
+771%
operating profit
4.5m
-655%
gross margin
39%
+109.43%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
September 2023net assets
3.3m
-3.85%
total assets
6.3m
+7.76%
cash
15.7k
-0.37%
net assets
Total assets minus all liabilities
Similar Companies
rudipharm limited company details
company number
09987370
Type
Private limited with Share Capital
industry
21100 - Manufacture of basic pharmaceutical products
incorporation date
February 2016
age
9
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
September 2023
previous names
north star healthcare limited (February 2020)
accountant
-
auditor
KISHENS LIMITED
address
unit 6 i.o.centre, salbrook road ind estate, salfords, surrey, RH1 5GJ
Bank
-
Legal Advisor
-
rudipharm limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to rudipharm limited.
rudipharm limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for RUDIPHARM LIMITED. This can take several minutes, an email will notify you when this has completed.
rudipharm limited Companies House Filings - See Documents
| date | description | view/download |
|---|
